These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 5377613)
1. Sequential chemotherapy with cyclophosphamide (NSC-26271) and cytosine arabinoside (NSC-63878) in mice with advanced leukemia L1210. Hoffman GS; Kline I; Gang M; Tyrer DD; Goldin A; Mantel N; Venditti JM Cancer Chemother Rep; 1969 Oct; 53(5):265-71. PubMed ID: 5377613 [No Abstract] [Full Text] [Related]
2. Effect of different doses of methotrexate (NSC-740), cytosine arabinoside (NSC-63878), and cyclophosphamide (NSC-26271) on drug resistance in mice with L1210 leukemia. Schmid FA; Hutchison DJ Cancer Chemother Rep; 1972 Aug; 56(4):473-81. PubMed ID: 5081590 [No Abstract] [Full Text] [Related]
3. Chronochemotherapy of L1210 leukemic mice with cytosine arabinoside or cyclophosphamide. Rose WC; Trader MW; Laster WR; Schabel FM Cancer Treat Rep; 1978 Sep; 62(9):1337-49. PubMed ID: 688277 [No Abstract] [Full Text] [Related]
4. A computer model for tumor growth and chemotherapy, and its application to L1210 leukemia treated with cytosine arabinoside (NSC-63878). Shackney SE Cancer Chemother Rep; 1970 Dec; 54(6):399-429. PubMed ID: 5527022 [No Abstract] [Full Text] [Related]
5. Value of cytosine arabinoside (NSC-63878) plus 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) therapy in advanced murine L1210 leukemia and enhancement of the combination with sequential doses of methotrexate (NSC-740) or 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962). Kline I; Woodman RJ; Gang M; Cysyk RL; Venditti JM Cancer Chemother Rep; 1973; 57(3):291-8. PubMed ID: 4751255 [No Abstract] [Full Text] [Related]
6. Influence of route of administration on antileukemic activity of cytosine arabinoside (NSC-63878) in advanced leukemia L1210 in mice. Kline I; Tyrer DD; Gang M; Venditti JM; Goldin A Cancer Chemother Rep; 1968 Apr; 52(3):399-404. PubMed ID: 5670722 [No Abstract] [Full Text] [Related]
7. Studies of the L1210 antileukemic activity of O-2,2'-cyclocytidine, monoacetate (anhydro-ara-C; NSC-129220)--comparison with cytosine arabinoside (NSC-63878) with respect to treatment schedule dependency. Venditti JM; Baratta MC; Greenberg NH; Abbott BJ; Kline I Cancer Chemother Rep; 1972 Aug; 56(4):483-92. PubMed ID: 5081591 [No Abstract] [Full Text] [Related]
8. Influence of mitotic cycle inhibitors on the antileukemic activity of cytosine arabinoside (NSC-63878) in mice bearing leukemia L1210. Vadlamudi S; Goldin A Cancer Chemother Rep; 1971 Dec; 55(5):547-55. PubMed ID: 5159846 [No Abstract] [Full Text] [Related]
9. Influence of the stage of advancement of leukemia L1210 in mice on the optimal schedule of treatment of cytosine arabinoside (NSC-63878). Kline I; Woodman RJ; Gang M; Sirica A; Venditti JM; Goldin A Cancer Chemother Rep; 1972 Jun; 56(3):327-34. PubMed ID: 19051491 [TBL] [Abstract][Full Text] [Related]
11. Chronochemotherapy: L 1210 leukemia and beyond. Halberg F; Nelson W; Cornélissen G; Haus E; Scheving LE; Good RA Chronobiologia; 1979; 6(3):203-11. PubMed ID: 520097 [TBL] [Abstract][Full Text] [Related]
12. Selective chemotherapy for advanced murine L 1210 leukemia by combination of 2' deoxycytidine and lethal doses of cytosine-arabinoside. Buchman VM; Svet-Maoldavsky GJ; Lichinitser MR; Mkheidze DM Biomedicine; 1977 Jul; 27(5):179-80. PubMed ID: 922116 [TBL] [Abstract][Full Text] [Related]
13. [Selective treatment of leukemia L1210 with combination of deoxycytidine and lethal doses of cytosine arabinoside]. Bukhman VM; Lichinitser MR; Svet-Moldavskiĭ GIa; Mkheidze DM Biull Eksp Biol Med; 1978 Mar; 85(3):340-3. PubMed ID: 276385 [TBL] [Abstract][Full Text] [Related]
14. Cytosine arabinoside (NSC-63878)--clinical brochure. Livingston RB; Carter SK Cancer Chemother Rep 3; 1968 Dec; 1(1):179-205. PubMed ID: 4989814 [No Abstract] [Full Text] [Related]
15. Effect of combined therapy with cytosine arabinoside (NSC-63878) and l,3-bis-(2-chloroethyl)-1-nitrosourea (NSC-409962) on sarcoma 180 and L1210 in vivo. Mizuno NS; Humphrey EW Cancer Chemother Rep; 1969 Sep; 53(4):215-21. PubMed ID: 5384462 [No Abstract] [Full Text] [Related]
16. Enhancement of the cancer chemotherapeutic effect of cytosine arabinoside entrapped in liposomes on mouse leukemia L-1210. Kobayashi T; Tsukagoshi S; Sakurai Y Gan; 1975 Dec; 66(6):719-20. PubMed ID: 1225724 [No Abstract] [Full Text] [Related]
17. Single versus combination chemotherapy of L1210 leukemia. Koza I; Balázová E; Ujházy V Neoplasma; 1980; 27(6):691-6. PubMed ID: 7254424 [TBL] [Abstract][Full Text] [Related]
18. Combination chemotherapy with cytosine arabinoside, L-asparaginase, and 6-azauridine for transplantable murine leukemias. Avery TL; Roberts D Cancer Res; 1973 Apr; 33(4):791-9. PubMed ID: 4696479 [No Abstract] [Full Text] [Related]
19. Letter: Proposed new derivative of cytosine arabinoside (NSC-63878) to circumvent resistance. Cysyk RL Cancer Chemother Rep; 1974; 58(3):298-9. PubMed ID: 4842665 [No Abstract] [Full Text] [Related]
20. Evaluation of antileukemic agents in advanced leukemia L1210 in mice. IX. Kline I; Gang M; Tyrer DD; Venditti JM; Artis EW; Goldin A Cancer Chemother Rep 2; 1971 Apr; 2(1):65-133. PubMed ID: 5565539 [No Abstract] [Full Text] [Related] [Next] [New Search]